Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease
Benoît Melchior(Therapeutics Clinical Research), Yusuf Yazıcı(Io Therapeutics (United States))
Cited by 64
Related Papers
Behçet syndrome: a contemporary view
|Nature Reviews Rheumatology|2018|438
Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study
|New England Journal of Medicine|2015|241
Behçet syndrome
|Nature Reviews Disease Primers|2021|175